LifeStance Health Group (NASDAQ:LFST – Free Report) had its target price trimmed by Barclays from $8.00 to $6.00 in a research report sent to investors on Friday, Benzinga reports. The brokerage currently has an underweight rating on the stock.
Separately, Morgan Stanley reissued an overweight rating and set a $10.00 price target on shares of LifeStance Health Group in a research note on Monday, April 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of Hold and an average price target of $8.40.
Get Our Latest Analysis on LFST
LifeStance Health Group Price Performance
LifeStance Health Group (NASDAQ:LFST – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. LifeStance Health Group had a negative return on equity of 11.92% and a negative net margin of 15.69%. The firm had revenue of $312.30 million for the quarter, compared to analyst estimates of $305.85 million. During the same quarter in the prior year, the company earned ($0.13) EPS. LifeStance Health Group’s revenue was up 20.3% on a year-over-year basis. On average, research analysts forecast that LifeStance Health Group will post -0.25 earnings per share for the current year.
Insider Activity at LifeStance Health Group
In related news, insider Danish J. Qureshi sold 150,000 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $5.21, for a total value of $781,500.00. Following the completion of the sale, the insider now directly owns 439,002 shares in the company, valued at approximately $2,287,200.42. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, insider Danish J. Qureshi sold 150,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $5.21, for a total transaction of $781,500.00. Following the completion of the sale, the insider now directly owns 439,002 shares in the company, valued at $2,287,200.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Summit Partners Growth Equity sold 3,802,345 shares of the firm’s stock in a transaction dated Friday, May 24th. The shares were sold at an average price of $5.89, for a total value of $22,395,812.05. Following the sale, the insider now owns 41,932,358 shares of the company’s stock, valued at $246,981,588.62. The disclosure for this sale can be found here. In the last three months, insiders sold 4,037,438 shares of company stock worth $23,647,876. Corporate insiders own 6.60% of the company’s stock.
Institutional Trading of LifeStance Health Group
Large investors have recently modified their holdings of the business. Bessemer Group Inc. lifted its position in shares of LifeStance Health Group by 43.4% during the first quarter. Bessemer Group Inc. now owns 9,143 shares of the company’s stock worth $56,000 after purchasing an additional 2,768 shares during the last quarter. CIBC Asset Management Inc bought a new position in shares of LifeStance Health Group during the second quarter worth about $53,000. Assetmark Inc. lifted its position in shares of LifeStance Health Group by 21.6% during the fourth quarter. Assetmark Inc. now owns 11,895 shares of the company’s stock worth $93,000 after purchasing an additional 2,114 shares during the last quarter. Stratos Wealth Partners LTD. bought a new position in shares of LifeStance Health Group during the fourth quarter worth about $93,000. Finally, Allen Investment Management LLC bought a new position in shares of LifeStance Health Group during the first quarter worth about $79,000. 85.50% of the stock is currently owned by institutional investors and hedge funds.
LifeStance Health Group Company Profile
LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.
Featured Articles
- Five stocks we like better than LifeStance Health Group
- Are Penny Stocks a Good Fit for Your Portfolio?
- It’s Time to Take a Second Look at Take-Two Interactive Stock
- Using the MarketBeat Dividend Yield Calculator
- Cirrus Logic Stock Surges on Strong Apple iPhone Upgrade Cycle
- How to Start Investing in Real Estate
- The Trade Desk : Premium Digital Ad Demand Fuels Record Growth
Receive News & Ratings for LifeStance Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeStance Health Group and related companies with MarketBeat.com's FREE daily email newsletter.